Shilpa Gupta: Novel approach of intermittent IO in mRCC

Shilpa Gupta shared a post on X by María Natalia Gandur Quiroga about a recent paper by Moshe Ornstein et al. published in Clinical Genitourinary Cancer.

“Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab”

Authors: Moshe Ornstein, Laeth George, Wei Wei, Shilpa Gupta, Brian Rini et al.

“Congrats Moshe Ornstein, Cleveland Clinic on this novel approach of intermittent IO in mRCC! An area of unmet need.”

Quoting María Natalia Gandur Quiroga’s post:

“Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.

Sustained Disease Control: A subset of patients with metastatic renal cell carcinoma (mRCC) who discontinue immunotherapy can maintain disease control without the need for continuous treatment.

Treatment-Free Interval (TFI): 78% of patients remained off therapy, with a median treatment-free interval of 34.3 months.

Need for Further Studies: Additional studies on therapy de-escalation in mRCC are needed to reduce the physical and financial toxicity associated with prolonged immunotherapy.

Biomarkers: No clear clinical, radiographic, or serologic biomarkers were identified to guide early discontinuation of immunotherapy.

Safe Reinduction: Reinduction with ipilimumab/nivolumab was well-tolerated, with no grade 3 or higher toxicities in patients who experienced disease progression after initial discontinuation.”

Sources: Shilpa Gupta/X and María Natalia Gandur Quiroga/X

More posts by Shilpa Gupta on oncodaily.com

Shilpa Gupta is the Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic.

Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies.

Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.